JAMES MESCHIA

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. Hasan T, Barrett K, Brott T, Badi M, Lesser E, Hodge D, et al. Severity of White Matter Hyperintensities and Effects on All-Cause Mortality in the Mayo Clinic Florida Familial Cerebrovascular Diseases Registry. Mayo Clin Proc. 2019;94:408-416 pubmed publisher
    ..Associations between all-cause mortality rates across the severity range of WMH were observed in the Registry. Further studies are warranted to understand the clinical importance of WMH in other clinical populations. ..
  2. Meschia J. Alpha-1 antitrypsin dysfunction and large artery stroke. Proc Natl Acad Sci U S A. 2017;114:3555-3557 pubmed publisher
  3. Cannistraro R, Meschia J. The Clinical Dilemma of Anticoagulation Use in Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation. Curr Cardiol Rep. 2018;20:106 pubmed publisher
    ..In patients with AF, antithrombotics should be avoided in CAA with predominant ICH, cSS, or cSAH features. Those with ??2 CMB require in-depth risk-benefit analysis using a multidisciplinary approach. ..
  4. request reprint
    Meschia J, Miller D, Brott T. Thrombolytic treatment of acute ischemic stroke. Mayo Clin Proc. 2002;77:542-51 pubmed
  5. Meschia J. New information on the genetics of stroke. Curr Neurol Neurosci Rep. 2011;11:35-41 pubmed publisher
  6. Meschia J, Hopkins L, Altafullah I, Wechsler L, Stotts G, Gonzales N, et al. Time From Symptoms to Carotid Endarterectomy or Stenting and Perioperative Risk. Stroke. 2015;46:3540-2 pubmed publisher
    ..Time from symptoms to carotid endarterectomy or carotid artery stenting did not alter periprocedural safety, supporting early revascularization regardless of modality. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00004732. ..
  7. Meschia J, Merrill P, Soliman E, Howard V, Barrett K, Zakai N, et al. Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke. 2010;41:581-7 pubmed publisher
    ..28; 0.13 to 0.60). Blacks were less likely than whites to be aware of having AF or to be treated with warfarin. Potential reasons for the racial disparity in warfarin treatment warrant further investigation. ..
  8. Meschia J, Brott T, Brown R, Crook R, Worrall B, Kissela B, et al. Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Ann Neurol. 2005;58:351-61 pubmed
    ..There was no evidence of association between variants of ALOX5AP and ischemic stroke. These data suggest that common variants in PDE4D may contribute to the genetic risk for ischemic stroke in multiple populations. ..
  9. Meschia J, Worrall B, Rich S. Genetic susceptibility to ischemic stroke. Nat Rev Neurol. 2011;7:369-78 pubmed publisher

More Information

Publications10

  1. Meschia J, Klaas J, Brown R, Brott T. Evaluation and Management of Atherosclerotic Carotid Stenosis. Mayo Clin Proc. 2017;92:1144-1157 pubmed publisher
    ..Whether revascularization is better than contemporary medical therapy for asymptomatic extracranial carotid stenosis is a subject of several ongoing randomized clinical trials in the United States and internationally. ..